which targeted the SIRPα receptor with which CD47 interacts. Last year, AbbVie also pulled out of a $1.3 billion R&D partnership with I-Mab on lemzoparlimab for MDS and AML, for undisclosed ...

SIRPα interacts with CD47, a cell surface molecule often over-expressed on cancer cells. The CD47-SIRPα axis limits the antibody-mediated destruction of cancer cells through a ‘don’t eat me ...

The most advanced molecules in its pipeline target the IC proteins CD47, a ligand of signal-regulatory protein-α (SIRPα), and PD-L1, a ligand of programmed cell death protein 1 (PD-1 ...

image: Pal-DMPOP由CD47/SIRPα的阻断肽、PD-1/PD-L1的D肽阻断剂，以及N端的棕榈酸尾巴和linker组成，该设计能让Pal-DMPOP抵抗血清中酶的 ...

Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloid leukaemia (AML).